Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials

Publication date: Available online 13 November 2017
Source:Journal of Clinical Epidemiology
Author(s): Aviv Ladanie, John P.A. Ioannidis, Randall S. Stafford, Hannah Ewald, Heiner C. Bucher, Lars G. Hemkens
BackgroundOff-label drug use is highly prevalent, but controversial and often discouraged assuming generally inferior medical effects associated with off-label use.MethodsWe searched Medline, PubMed Health and the Cochrane Library up to May 2015 for systematic reviews including meta-analyses of randomized clinical trials (RCTs) comparing off-label and approved drugs head-to-head in any population and on any medical outcome. We combined the comparative effects in meta-analyses providing summary odds ratios (sOR) for each treatment comparison and outcome, and then calculated an overall summary of the sOR across all comparisons (ssOR).ResultsWe included 25 treatment comparisons with 153 RCTs and 24 592 patients. In six of 25 comparisons (24%), off-label drugs were significantly superior (five of 25) or inferior (one of 25) to approved treatments. There was substantial statistical heterogeneity across comparisons (I²=43%). Overall, off-label drugs were more favorable than approved treatments (ssOR 0.72; 95% CI=0.54-0.95). Analyses of patient-relevant outcomes were similar (statistical significant differences in 24% (six of 25); ssOR 0.74; 95% CI=0.56-0.98; I²=60%). Analyses of primary outcomes of the systematic reviews (n=22 comparisons) indicated less heterogeneity and no statistically significant difference overall (ssOR 0.85; 95% CI=0.67-1.06; I²=0%).ConclusionsApproval status does not reliably indicate which drugs are more favorable in situations with clinical trial evidence comparing off-label with approved use. Drug effectiveness assessments without considering off-label use may provide incomplete information. To ensure that patients receive the best available care, funding, policy, reimbursement, and treatment decisions should be evidence based considering the entire spectrum of available therapeutic choices.



from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2htjqMK
via IFTTT